Rememax Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 27-12-2024
- Paid Up Capital ₹ 0.10 M
as on 27-12-2024
- Company Age 11 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 71.00 K
as on 27-12-2024
- Revenue %
(FY 2020)
- Ebitda
- Net Worth -92.95%
(FY 2020)
- Total Assets 28.13%
(FY 2020)
About Rememax Pharmaceuticals
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹71,000.00, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Vineet Khemani, Rajkumari Khemani, and Vinty Khemani serve as directors at the Company.
- CIN/LLPIN
U51909WB2013PTC193479
- Company No.
193479
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 May 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Rememax Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vineet Khemani  | Director | 20-May-2013 | Current |
| Rajkumari Khemani | Director | 21-May-2013 | Current |
| Vinty Khemani | Director | 29-Sep-2015 | Current |
Financial Performance of Rememax Pharmaceuticals.
Rememax Pharmaceuticals Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth observed a substantial decline by a decrease of 92.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Rememax Pharmaceuticals?
In 2017, Rememax Pharmaceuticals had a promoter holding of 90.00% and a public holding of 10.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pharmakon Distributors Private LimitedActive 11 years 7 monthsVineet Khemani, Rajkumari Khemani and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Overseas Bank Creation Date: 25 Jun 2021 | ₹0.07 M | Satisfied |
How Many Employees Work at Rememax Pharmaceuticals?
Unlock and access historical data on people associated with Rememax Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rememax Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rememax Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
